Industry News

• Alexion completes acquisition of Enobia Pharma Corp.  Alexion announced that the Company has completed its previously announced acquisition of 100% of the capital stock of Enobia Pharma Corp., a private biopharmaceutical company focused on the development of therapies to treat patients with ultra-rare and life-threatening genetic metabolic disorders.
  February 07, 2012  
• Merck announces top-line results of TRA-2P study of Vorapaxar  Merck announced the top-line results of the TRA-2P (Thrombin Receptor Antagonist) study of vorapaxar. Merck is developing vorapaxar, an investigational oral Protease Activated Receptor 1 thrombin receptor antagonist, for the prevention of thrombosis.
  February 07, 2012  
• New study evaluates Cialis(R) in parallel with Tamsulosin  Eli Lilly announced a Phase III study, published online by European Urology, showed both Cialis® (tadalafil) and tamsulosin significantly improved scores on the International Prostate Symptom Score, compared to placebo, in men with signs and symptoms suggestive of benign prostatic hyperplasia.
  February 07, 2012  
• Boston Scientific WallFlex® enteral stents shown to be safe and effective in three trials  Boston Scientific announced positive results from three studies of the WallFlex® Enteral Stent Systems, a family of self-expanding metal stents used to alleviate obstructive symptoms caused by cancers of the gastrointestinal tract.
  February 07, 2012  
• Luminex reports fourth quarter and full year 2011 results  Luminex reported fourth quarter 2011 revenue was $47.9 million, a 16 percent increase over the fourth quarter of 2010. GAAP net income for the fourth quarter of 2011 was $3.4 million, or $0.08 per diluted share.
  February 06, 2012  
• United Therapeutics receives Paragraph IV notice letter for Remodulin from Sandoz   United Therapeutics announced receipt of a Paragraph IV Certification Notice Letter on February 3, 2012 from Sandoz advising that Sandoz has submitted an ANDA to the FDA requesting approval to market a generic version of the 10 mg/mL strength of Remodulin® (treprostinil) injection.
  February 06, 2012  
• Merck updates development program for Suvorexant  Merck reported that the two pivotal Phase III efficacy trials for suvorexant have been completed and, based on the positive results of these studies, Merck plans to file a New Drug Application for suvorexant with the FDA in 2012.
  February 06, 2012  
• Genomic Health announces year-end 2011 financial results  Genomic Health reported total revenue for the year ended December 31, 2011 increased to $206.1 million versus $178.1 million in 2010, an increase of 16 percent. Net income was $7.8 million for the year ended December 31, 2011 versus $4.3 million in 2010.
  February 06, 2012  
• Cardinal Health Canada and Futuremed announce further extension of offer  Futuremed Healthcare Products Corporation and Cardinal Health Canada Inc. announced that the expiry time of the offer by Cardinal Health Canada to acquire all of the outstanding common shares of Futuremed for CAD $8.15 per Common Share in cash has been further extended until February 16, 2012.
  February 06, 2012  
• SurModics reports first quarter fiscal year 2012 results  SurModics reported revenue for the first quarter of 2012 totaled $11.9 million, a 5% decline from the $12.5 million reported in the first quarter of last year. Diluted EPS was $0.12 for the first quarter EPS of $0.16 for the same period last year.
  February 06, 2012  

   (next 10 articles)